Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
22
MED Quote, Financials, Valuation and Earnings
Last price:
$11.32
Seasonality move
:
11.84%
Day range:
$11.12 - $11.32
52-week range:
$10.36 - $18.59
Dividend yield:
0%
P/E ratio:
539.71x
P/S ratio:
0.29x
P/B ratio:
0.58x
Volume:
113K
Avg. volume:
258.7K
1-year change:
-33.53%
Market cap:
$124M
Revenue:
$602.5M
EPS (TTM):
$0.02
Analysts' Opinion
-
Consensus RatingMedifast, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $15.00, Medifast, Inc. has an estimated upside of 32.98% from its current price of $11.28.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $15.00 representing 100% downside risk from its current price of $11.28.
Fair Value
-
According to the consensus of 1 analyst, Medifast, Inc. has 32.98% upside to fair value with a price target of $15.00 per share.
MED vs. S&P 500
-
Over the past 5 trading days, Medifast, Inc. has underperformed the S&P 500 by -8.69% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Medifast, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Medifast, Inc. revenues have been falling on a year-over-year basis for 13 quarters in a row. In the most recent quarter Medifast, Inc. reported revenues of $89.4M.
Earnings Growth
-
Medifast, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Medifast, Inc. reported earnings per share of -$0.21.
Enterprise value:
-37.3M
EV / Invested capital:
-0.16x
Price / LTM sales:
0.29x
EV / EBIT:
-36.82x
EV / Revenue:
-0.09x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-57.69x
Price / Operating cash flow:
192.00x
Enterprise value / EBITDA:
-2.88x
Gross Profit (TTM):
$311.3M
Return On Assets:
0.09%
Net Income Margin (TTM):
0.06%
Return On Equity:
0.12%
Return On Invested Capital:
0.11%
Operating Margin:
-4.56%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $1.2B | $674.5M | $429.7M | $140.2M | $89.4M | |
| Gross Profit | $880.3M | $497.8M | $311.3M | $105.7M | $62.2M | |
| Operating Income | $171M | $10.8M | -$5.7M | $2.1M | -$4.1M | |
| EBITDA | $188.6M | $25.9M | $13M | $5.3M | -$629K | |
| Diluted EPS | $10.97 | $0.67 | $0.02 | $0.10 | -$0.21 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $301.1M | $229.6M | $224.3M | $225M | $207.8M | |
| Total Assets | $371.4M | $326.4M | $320M | $291.2M | $268.2M | |
| Current Liabilities | $160.9M | $154.3M | $110.1M | $72.4M | $46.7M | |
| Total Liabilities | $175.1M | $175.8M | $127M | $83.9M | $53.5M | |
| Total Equity | $196.2M | $150.5M | $193M | $207.3M | $214.7M | |
| Total Debt | $14.2M | $21.6M | $16.9M | $11.5M | $6.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $188.9M | $39.9M | $7.2M | $9.1M | $12.1M | |
| Cash From Investing | -$59.4M | -$17.8M | -$22.4M | -$1.8M | -$14.3M | |
| Cash From Financing | -$86.2M | -$19.4M | -$566K | -$3K | -- | |
| Free Cash Flow | $174.3M | $33.8M | $646K | $7.7M | $10.8M | |
MED
Sector
Market Cap
$124M
$122.6M
Price % of 52-Week High
60.68%
70.49%
Dividend Yield
0%
0%
Shareholder Yield
1.16%
2.3%
1-Year Price Total Return
-33.53%
-7.14%
Beta (5-Year)
0.481
0.255
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$11.73
200-day SMA
Sell
Level
$13.14
Bollinger Bands (100)
Sell
Level
11.56 - 13.9
Chaikin Money Flow
Buy
Level
25.6M
20-day SMA
Sell
Level
$11.44
Relative Strength Index (RSI14)
Sell
Level
44.61
ADX Line
Sell
Level
24.75
Williams %R
Neutral
Level
-70.8316
50-day SMA
Sell
Level
$11.72
MACD (12, 26)
Sell
Level
-0.01
25-day Aroon Oscillator
Buy
Level
60
On Balance Volume
Sell
Level
-25.2M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (4.937)
Buy
CA Score
(Annual)
Level (1.0964)
Buy
Beneish M-Score
(Annual)
Level (-4.133)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (23.0166)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (9)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Medifast, Inc. is a health and wellness company, which engages in the provision of habit-based and coach-guided lifestyle solutions called OPTAVIA. It offers and ships OPTAVIA products directly to its customers. It focuses on coaching healthy habits through a health transformational system. The company was founded by William Vitale in 1980 and is headquartered in Baltimore, MD.
Stock Forecast FAQ
In the current month, MED has received 0 Buy ratings 1 Hold ratings, and 0 Sell ratings. The MED average analyst price target in the past 3 months is $15.00.
-
Where Will Medifast, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Medifast, Inc. share price will rise to $15.00 per share over the next 12 months.
-
What Do Analysts Say About Medifast, Inc.?
Analysts are divided on their view about Medifast, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Medifast, Inc. is a Sell and believe this share price will drop from its current level to $15.00.
-
What Is Medifast, Inc.'s Price Target?
The price target for Medifast, Inc. over the next 1-year time period is forecast to be $15.00 according to 1 Wall Street analyst, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is MED A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Medifast, Inc. is a Hold. 1 of 1 analysts rates the stock a Hold at this time.
-
How Can I Buy Shares Of MED?
You can purchase shares of Medifast, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Medifast, Inc. shares.
-
What Is The Medifast, Inc. Share Price Today?
Medifast, Inc. was last trading at $11.32 per share. This represents the most recent stock quote for Medifast, Inc.. Yesterday, Medifast, Inc. closed at $11.28 per share.
-
How To Buy Medifast, Inc. Stock Online?
In order to purchase Medifast, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get MED Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
MED
Sector
P/E ratio
539.71x
16.77x
PEG ratio
--
0.13x
P/B ratio
0.58x
1.48x
Price / LTM sales
0.29x
0.51x
Growth Metrics
MED
Sector
Revenue growth
-36.21%
2.99%
Earnings growth
-299.9%
5%
Revenue (5-year growth)
-3.33%
3.31%
Earnings forecast
-$0.36
$0.32
Profitability
MED
Sector
Profitability FY 2024
$444.6M
$260.8M
Return on invested capital
0.11%
4.37%
Return on assets
0.09%
3.07%
Return on equity
0.12%
7.5%
Earnings Date
Last Earnings Date
Nov
3
Next Earnings Date
Feb
19
Estimated Next Earnings Date
Feb
2
Balance Sheet
MED
Sector
Total cash
$173.5M
$87.3M
Short term investments
$71.4M
$32.9M
Total assets
$293.2M
$1.1B
Long term debt
$6.8M
$6.7M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
87
HUT alert for Dec 25
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
60
GPCR alert for Dec 25
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
